Journal
ANTIBIOTICS-BASEL
Volume 10, Issue 1, Pages -Publisher
MDPI
DOI: 10.3390/antibiotics10010077
Keywords
valganciclovir; ganciclovir; serum levels; therapeutic drug monitoring; CMV infection
Categories
Funding
- Instituto de Salud Carlos III Madrid Spain
- European Social Fund (FSE) [CM18/00030]
Ask authors/readers for more resources
This prospective study aimed to evaluate the adequacy of valganciclovir/ganciclovir doses, assess interpatient variability in ganciclovir serum levels, identify predictive factors for this variability, and evaluate the clinical impact. The study found challenges in achieving adequate dosing of valganciclovir/ganciclovir and significant inter-individual variability in serum levels. Further research is needed to confirm these results and determine if therapeutic drug monitoring could improve outcomes in specific clinical situations.
Valganciclovir (VGCV) and ganciclovir (GCV) doses must be adjusted according to indication, renal function and weight. No specific therapeutic exposure values have been established. We aimed to evaluate the adequacy of VGCV/GCV doses, to assess the interpatient variability in GCV serum levels, to identify predictive factors for this variability and to assess the clinical impact. This is a prospective study at a tertiary institution including hospitalized patients receiving VGCV/GCV prophylaxis or treatment. Adequacy of the antiviral dose was defined according to cytomegalovirus guidelines. Serum levels were determined using High-Performance Liquid Chromatography. Blood samples were drawn at least 3 days after antiviral initiation. Outcome was considered favorable if there was no evidence of cytomegalovirus infection during prophylaxis or when a clinical and microbiological resolution was attained within 21 days of treatment and no need for drug discontinuation due to toxicity. Seventy consecutive patients [74.3% male/median age: 59.2 years] were included. VGCV was used in 25 patients (35.7%) and GCV in 45 (64.3%). VGCV/GCV initial dosage was deemed adequate in 47/70 cases (67.1%), lower than recommended in 7/70 (10%) and higher in 16/70 (22.9%). Large inter-individual variability of serum levels was observed, with median trough levels of 2.3 mg/L and median peak levels of 7.8 mg/L. Inadequate dosing of VGCV/GCV and peak levels lower than 8.37 or greater than 11.86 mg/L were related to poor outcome. Further studies must be performed to confirm these results and to conclusively establish if VGCV/GCV therapeutic drug monitoring could be useful to improve outcomes in specific clinical situations.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available